Ardent Health (NYSE:ARDT – Get Free Report) is expected to post its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect Ardent Health to post earnings of $0.18 per share and revenue of $1.5778 billion for the quarter. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 10:00 AM ET.
Ardent Health (NYSE:ARDT – Get Free Report) last issued its earnings results on Wednesday, March 4th. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.03). Ardent Health had a return on equity of 14.30% and a net margin of 2.15%.The company had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.63 billion. On average, analysts expect Ardent Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Ardent Health Price Performance
ARDT traded down $0.22 on Tuesday, hitting $9.82. 66,635 shares of the company were exchanged, compared to its average volume of 383,920. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.85 and a current ratio of 1.97. The business’s fifty day moving average is $9.25 and its 200 day moving average is $9.95. Ardent Health has a fifty-two week low of $8.07 and a fifty-two week high of $15.48. The firm has a market capitalization of $1.41 billion, a P/E ratio of 10.22 and a beta of 0.57.
Institutional Trading of Ardent Health
Analyst Upgrades and Downgrades
Several brokerages have weighed in on ARDT. Leerink Partners lowered their target price on shares of Ardent Health from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Friday, March 6th. JPMorgan Chase & Co. lowered their target price on shares of Ardent Health from $12.00 to $11.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. Zacks Research upgraded shares of Ardent Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, March 25th. Royal Bank Of Canada lowered their target price on shares of Ardent Health from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Monday, March 9th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Ardent Health in a research report on Monday, December 29th. Seven equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $14.25.
Read Our Latest Analysis on ARDT
Ardent Health Company Profile
Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.
Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.
See Also
Receive News & Ratings for Ardent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardent Health and related companies with MarketBeat.com's FREE daily email newsletter.
